Specialty Oncology
-
Featured
Mass General Offers Novel, Kidney-saving Urothelial Cancer Treatment
Mitomycin chemoablation with a mitomycin gel, a novel treatment offered in the Department of Urology at Massachusetts General Hospital, can avoid the need for surgical removal of the kidney and ureter in patients with upper tract urothelial cancer.
-
Featured
Using Machine Learning to Predict Prostate Cancer Progression During Active Surveillance
Madhur Nayan, MDCM, PhD, and Adam S. Feldman, MD, MPH, and colleagues created the first machine learning models for predicting prostate cancer progression during active surveillance and found they outperformed traditional logistic regression.
-
Case Series: Mucinous Adenocarcinoma of the Prostatic Urethra After Brachytherapy for Prostatic Adenocarcinoma
Massachusetts General Hospital researchers present the first case series of brachytherapy-associated mucinous adenocarcinoma of the prostatic urethra, reviewing clinical and pathologic differences from its radiation-independent counterpart and concluding it's associated with lower stage and less aggressive behavior.
-
Combination of Darolutamide, ADT, and Docetaxel Improves Survival of Patients With Metastatic, Hormone-sensitive Prostate Cancer
Matthew R. Smith, MD, PhD, and colleagues present compelling evidence that survival is significantly better among patients with metastatic, hormone-sensitive prostate cancer who receive darolutamide, androgen-deprivation therapy, and docetaxel than those who receive androgen-deprivation therapy and docetaxel alone.
-
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
Shenglin Mei, PhD, Philip J. Saylor, MD, David B. Sykes, MD, PhD, and colleagues found that simultaneous expression of four specific genes predicts survival and metastasis in human clear cell renal cell carcinoma, and they identified other potential therapeutic targets.
-
Distinct Cellular Dynamics Are Associated With Response to CAR-T Therapy for B-Cell Lymphoma
Marcela V. Maus, MD, PhD, Gad Getz, PhD and colleagues observed that even small increases in CAR regulatory T cells contributed to relapse after axicabtagene ciloleucel treatment of refractory large B-cell lymphoma. This and other findings may optimize the design and individualization of CAR T-cell therapies.
Mass General Cancer Center Contributors
-
Andrew T. Chan, MD, MPH
Daniel K. Podolsky Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
Maternal Consumption of Ultra-processed Foods Linked to Weight Gain in Offspring
-
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Improved Coping Explains Benefits of Integrated Palliative Care for Patients With Acute Myeloid Leukemia
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Case Series: Mucinous Adenocarcinoma of the Prostatic Urethra After Brachytherapy for Prostatic Adenocarcinoma
-
Joseph H. Schwab, MD, MS
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopaedic Surgery, Harvard Medical School
Recent Article
Two Mass General Research Groups Share Resources, Lab Space and a Vision for the Future
-
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Cancer Center, Professor of Medicine, Harvard Medical School
Recent Article
37 Biopsies, Nine Years: Mapping Evolution of Resistance to Melanoma Immunotherapy in a Former Complete Responder
-
Keyan Salari, MD, PhD
Urologic Surgeon, Department of Urology, Massachusetts General Hospital, Urologic Oncologist, Mass General Cancer Center, Co-Director, Prostate Cancer Genetics Program
Recent Article
Active Surveillance for Prostate Cancer
-
Marcela G. del Carmen, MD
Chief Medical Officer, Massachusetts General Physicians Organization and Massachusetts General Hospital, Gynecologic Oncologist, Department of Obstetrics and Gynecology, Clinician, Center for Gynecologic Oncology, Mass General Cancer Center
Recent Article
Review: Lesions of the Ovary and Fallopian Tube
-
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Distinct Cellular Dynamics Are Associated With Response to CAR-T Therapy for B-Cell Lymphoma
-
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Considering Both Tumor and Immune Features May Improve Prediction of Melanoma Outcomes After Checkpoint Inhibition
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Designing Leading-Edge Immunotherapy for Brain Cancer
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
